Literature DB >> 18385665

A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5' end of Pkd1.

P G Starremans1, X Li, P E Finnerty, L Guo, A Takakura, E G Neilson, J Zhou.   

Abstract

Autosomal dominant polycystic kidney disease, a leading cause of end-stage renal disease in adults, is characterized by progressive focal cyst formation in the kidney. Embryonic lethality of Pkd1-targeted mice limits the use of these mice. Here we developed a floxed allele of Pkd1 exons 2-6. Global deletion mutants developed polyhydramnios, hydrops fetalis, polycystic kidney and pancreatic disease. Somatic Pkd1 inactivation in the kidney was achieved by crossing Pkd1(flox) mice with transgenic mice expressing Cre controlled by a gamma-glutamyltranspeptidase promoter. These mutants developed cysts in both proximal and distal nephron segments and survived for about 4 weeks. Somatic loss of heterozygosity was shown in a reporter mouse strain to cause cystogenesis. Some cysts in young mice are positive for multiple tubular markers and a mesenchymal marker, suggesting a delay in tubular epithelial differentiation. A higher cell proliferation rate was observed in distal nephron segments probably accounting for the faster growth rate of distal cysts. Although we observed an overall increase in apoptosis in cystic kidneys, there was no difference between proximal or distal nephron segments. We also found increased cyclic AMP, aquaporin 2 and vasopressin type 2 receptor mRNA levels, and apical membrane translocation of aquaporin 2 in cystic kidneys, all of which may contribute to the differential cyst growth rate observed. The accelerated polycystic kidney phenotype of these mice provides an excellent model for studying molecular pathways of cystogenesis and to test therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385665     DOI: 10.1038/ki.2008.111

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  40 in total

1.  Fibroblast expression of an IκB dominant-negative transgene attenuates renal fibrosis.

Authors:  Tsutomu Inoue; Tsuneo Takenaka; Matsuhiko Hayashi; Toshiaki Monkawa; Jun Yoshino; Kouji Shimoda; Eric G Neilson; Hiromichi Suzuki; Hirokazu Okada
Journal:  J Am Soc Nephrol       Date:  2010-09-16       Impact factor: 10.121

Review 2.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 3.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 4.  Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.

Authors:  Takamitsu Saigusa; P Darwin Bell
Journal:  Physiology (Bethesda)       Date:  2015-05

5.  Inactivation of Pkd1 in principal cells causes a more severe cystic kidney disease than in intercalated cells.

Authors:  Kalani L Raphael; Kevin A Strait; Peter K Stricklett; R Lance Miller; Raoul D Nelson; Klaus B Piontek; Gregory G Germino; Donald E Kohan
Journal:  Kidney Int       Date:  2009-01-14       Impact factor: 10.612

6.  Pkd1 transgenic mice: adult model of polycystic kidney disease with extrarenal and renal phenotypes.

Authors:  Almira Kurbegovic; Olivier Côté; Martin Couillard; Christopher J Ward; Peter C Harris; Marie Trudel
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

7.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

8.  Disruption of polycystin-L causes hippocampal and thalamocortical hyperexcitability.

Authors:  Gang Yao; Chong Luo; Michael Harvey; Maoqing Wu; Taylor H Schreiber; Yanjun Du; Nuria Basora; Xuefeng Su; Diego Contreras; Jing Zhou
Journal:  Hum Mol Genet       Date:  2015-11-26       Impact factor: 6.150

9.  Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.

Authors:  Katharina Hopp; Cynthia J Hommerding; Xiaofang Wang; Hong Ye; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 10.121

10.  Emerging evidence of a link between the polycystins and the mTOR pathways.

Authors:  Alessandra Boletta
Journal:  Pathogenetics       Date:  2009-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.